rosuvastatin + omeprazole

Rosuvastatin + omeprazole is a combination of two small molecule drugs, each with distinct mechanisms and indications. Rosuvastatin is an HMG-CoA reductase inhibitor (statin) used primarily to lower LDL cholesterol and triglycerides, thereby reducing the risk of cardiovascular events such as heart attack and stroke. It works by inhibiting the enzyme HMG-CoA reductase in the liver, which plays a central role in cholesterol synthesis. Omeprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by irreversibly inhibiting the hydrogen/potassium ATPase enzyme system at the secretory surface of gastric parietal cells. It is indicated for conditions such as gastroesophageal reflux disease (GERD), peptic ulcer disease, and other acid-related disorders[6][8]. There are no known clinically significant pharmacokinetic interactions between rosuvastatin and omeprazole; both can generally be co-administered safely[1][2]. However, recent research suggests that PPIs like omeprazole may increase statin lactonization—a metabolic pathway associated with potential toxicity—though this has been more clearly demonstrated with atorvastatin than rosuvastatin[3].